Literature DB >> 26221207

Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells.

Zhengmao Zhang1, Zhen Xie1, Guangyu Sun1, Pingfang Yang1, Jia Li1, Hongfang Yang1, Shuang Xiao1, Yang Liu1, Hongbing Qiu1, Lijun Qin1, Chao Zhang2, Fenghua Zhang3, Baoen Shan2.   

Abstract

OBJECTIVE: To investigate the mechanisms for reversing drug resistance of cisplatin (DDP) by Hsp90 inhibitors (geldanamycin (GA), 17-AAG, 17-DMAG) in human ovarian cancer.
METHODS: Cell proliferation rate in DDP resistant human ovarian cancer cell line SKOV3/DDP and its parent cell line SKOV3 after treatment with Hsp90 inhibitors and/or DDP were tested by MTT assay, and the reversing fold (RF) of DDP by Hsp90 inhibitors was calculated. Cell cycle and cell apoptosis status after treatment were analyzed by flow cytometry. The expression of multiple drug resistance related genes was analyzed by RT-PCR and Western-blot.
RESULTS: All three tested Hsp90 inhibitors synergistically inhibited the cell proliferation of SKOV3 with DDP and enhanced the sensitivity of SKOV3/DDP cells to DDP. The RF of DDP by Hsp90 inhibitors were all more than two fold. GA caused cell cycle arrest in G2/M phasein SKOV3 cells. 17-AAG increased cell apoptosis but did not change cell cycle in SKOV3/DDP cells. The mRNA and protein expression levels of various drug resistant related genes including LRP, GST-π, p53, bcl-2, survivin, ERCC1, XRCC1, BRCA1 and BRCA2 were more dramatically altered by Hsp90 inhibitors and DDP in combination compared to Hsp90 inhibitors or DDP treatment alone.
CONCLUSIONS: Exposure of SKOV3/DDP cells to Hsp90 inhibitors and DDP in combination results in synergistic cytotoxic and pro-apoptotic effects. Hsp90 inhibitors reverse the drug resistance of SKOV3/DDP cells to DDP by modifying the expression of multiple drug resistance related genes.

Entities:  

Keywords:  Hsp90 inhibitors; Ovarian cancer; cisplatin; heat shock protein 90; resistance genes

Year:  2015        PMID: 26221207      PMCID: PMC4509152     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells.

Authors:  Chung S Lee; Yun J Kim; Seon A Lee; Soon C Myung; Wonyong Kim
Journal:  Basic Clin Pharmacol Toxicol       Date:  2012-04-16       Impact factor: 4.080

2.  Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.

Authors:  D Lu; H-C Shi; Z-X Wang; X-W Gu; Y J Zeng
Journal:  Br J Biomed Sci       Date:  2011       Impact factor: 3.829

3.  Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions.

Authors:  Mari Bunkholt Elstrand; Helene Tuft Stavnes; Claes G Tropé; Ben Davidson
Journal:  Hum Pathol       Date:  2011-08-23       Impact factor: 3.466

Review 4.  Fasting plasma glucose and incident heart failure risk: a population-based cohort study and new meta-analysis.

Authors:  Hassan Khan; Setor K Kunutsor; Jussi Kauhanen; Sudhir Kurl; Eiran Z Gorodeski; Amanda I Adler; Javed Butler; Jari A Laukkanen
Journal:  J Card Fail       Date:  2014-06-10       Impact factor: 5.712

5.  Increased ERCC1 protein expression is associated with suboptimal debulking in advanced epithelial ovarian cancer.

Authors:  Feili Lin; Kaiqing Lin; Xing Xie; Caiyun Zhou
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

6.  Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis.

Authors:  Konstantinos P Economopoulos; Theodoros N Sergentanis; Nikos F Vlahos
Journal:  Int J Gynecol Cancer       Date:  2010-07       Impact factor: 3.437

7.  Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer.

Authors:  Piotr Bodzek; Robert Partyka; Aleksandra Damasiewicz-Bodzek
Journal:  J Ovarian Res       Date:  2014-03-11       Impact factor: 4.234

8.  The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.

Authors:  Ming Geng; Lin Wang; Xin Chen; Ruixue Cao; Peifeng Li
Journal:  Diagn Pathol       Date:  2013-12-10       Impact factor: 2.644

9.  Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.

Authors:  József Dudás; Volker H Schartinger; Angela Romani; Gabriele Schweigl; Kristian Kordsmeyer; Patricia Irina Marta; Christoph Url; Florian Kral; Herbert Riechelmann
Journal:  Tumour Biol       Date:  2014-05-12

10.  [Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP].

Authors:  Jie Lv; Yufeng Tian
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-09
View more
  15 in total

1.  Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

Authors:  Chaoyun Pan; Jaemoo Chun; Dan Li; Austin C Boese; Jie Li; JiHoon Kang; Anna Umano; Yunhan Jiang; Lina Song; Kelly R Magliocca; Zhuo G Chen; Nabil F Saba; Dong M Shin; Taofeek K Owonikoko; Sagar Lonial; Lingtao Jin; Sumin Kang
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 2.  Hsp90 regulates autophagy and plays a role in cancer therapy.

Authors:  Benli Wang; Zongyan Chen; Feifei Yu; Qiao Chen; Yuxi Tian; Shumei Ma; Tiejun Wang; Xiaodong Liu
Journal:  Tumour Biol       Date:  2015-10-02

3.  Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Authors:  Daniela Kramer; Nadine Stark; Ramona Schulz-Heddergott; Norman Erytch; Shelley Edmunds; Laura Roßmann; Holger Bastians; Nicole Concin; Ute M Moll; Matthias Dobbelstein
Journal:  Cell Death Differ       Date:  2016-11-11       Impact factor: 15.828

4.  MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.

Authors:  Jing Tian; Yan-Ying Xu; Lian Li; Quan Hao
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  PI3K Inhibition Sensitize the Cisplatin-resistant Human Ovarian Cancer Cell OVCAR3 by Induction of Oxidative Stress.

Authors:  Sahar Baghal-Sadriforoush; Morteza Bagheri; Isa Abdi Rad; Fattah Sotoodeh Nejadnematalahi
Journal:  Rep Biochem Mol Biol       Date:  2022-01

6.  Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer.

Authors:  Peiguang Niu; Daohua Shi; Shusheng Zhang; Yanting Zhu; Jintuo Zhou
Journal:  Oncol Lett       Date:  2018-01-08       Impact factor: 2.967

7.  Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.

Authors:  Matthew D Cheeseman; Nicola E A Chessum; Carl S Rye; A Elisa Pasqua; Michael J Tucker; Birgit Wilding; Lindsay E Evans; Susan Lepri; Meirion Richards; Swee Y Sharp; Salyha Ali; Martin Rowlands; Lisa O'Fee; Asadh Miah; Angela Hayes; Alan T Henley; Marissa Powers; Robert Te Poele; Emmanuel De Billy; Loredana Pellegrino; Florence Raynaud; Rosemary Burke; Rob L M van Montfort; Suzanne A Eccles; Paul Workman; Keith Jones
Journal:  J Med Chem       Date:  2016-12-22       Impact factor: 7.446

8.  Transferrin Modified GSH Sensitive Hyaluronic Acid Derivative Micelle to Deliver HSP90 Inhibitors to Enhance the Therapeutic Efficacy of Brain Cancers.

Authors:  Tilahun Ayane Debele; Ping-Ching Wu; Yu-Feng Wei; Jian-Ying Chuang; Kwang-Yu Chang; Jui-Hung Tsai; Wen-Pin Su
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Novel Zinc(II) Complexes [Zn(atc-Et)₂] and [Zn(atc-Ph)₂]: In Vitro and in Vivo Antiproliferative Studies.

Authors:  Erica de O Lopes; Carolina G de Oliveira; Patricia B da Silva; Carlos E Eismann; Carlos A Suárez; Amauri A Menegário; Clarice Q F Leite; Victor M Deflon; Fernando R Pavan
Journal:  Int J Mol Sci       Date:  2016-05-21       Impact factor: 5.923

Review 10.  Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.

Authors:  Xueyong Liu; Zhan Zhang; Chunbo Deng; Yihao Tian; Xun Ma
Journal:  Oncotarget       Date:  2017-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.